E-LIB Suche - Ergebnisse für: Dillon, Magnus T

1

Durable responses to ATR inhibition with ceralasertib in tu..:

Dillon, Magnus T. ; Guevara, Jeane ; Mohammed, Kabir...
Journal of Clinical Investigation. 134 (2024) 2 - p. , 2024

Link: https://doi.org/10.1172/..

2

Predicting progression-free survival after systemic therapy..:

Ng, Kenrick ; Alfano, Giovanna ; Flores-Borja, Fabian...
eLife. 11 (2022) - p. , 2022

Link: https://doi.org/10.7554/..

3

Harnessing radiotherapy-induced NK-cell activity by combini..:

Patin, Emmanuel C ; Dillon, Magnus T ; Nenclares, Pablo...
Journal for ImmunoTherapy of Cancer. 10 (2022) 3 - p. e004306 , 2022

Link: https://doi.org/10.1136/..

4

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection i..:

McLaughlin, Martin ; Pedersen, Malin ; Roulstone, Victoria...
Molecular Therapy - Oncolytics. 16 (2020) - p. 238-249 , 2020

Link: https://doi.org/10.1016/..

5

Patritumab or placebo, with cetuximab plus platinum therapy..:

Forster, Martin D. ; Dillon, Magnus T. ; Kocsis, Judit...
European Journal of Cancer. 123 (2019) - p. 36-47 , 2019

Link: https://doi.org/10.1016/..

6

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Ce..:

Hafsi, Hind ; Dillon, Magnus T. ; Barker, Holly E....
Frontiers in Oncology. 8 (2018) - p. , 2018

Link: https://doi.org/10.3389/..

7

An orally bioavailable Chk1 inhibitor, CCT244747, sensitize..:

Patel, Radhika ; Barker, Holly E. ; Kyula, Joan...
Radiotherapy and Oncology. 122 (2017) 3 - p. 470-475 , 2017

Link: https://doi.org/10.1016/..

8

Durable responses to ATR inhibition with ceralasertib in tu..:

Dillon, Magnus T ; Guevara, Jeane ; Mohammed, Kabir...
https://discovery.ucl.ac.uk/id/eprint/10185901/1/175369.2-20240109104717-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf. , 2024

Link: https://discovery.ucl.ac..

9

Durable responses to ATR inhibition with ceralasertib in tu..:

Dillon, Magnus T ; Guevara, Jeane ; Mohammed, Kabir...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10786692/. , 2024

Link: http://www.ncbi.nlm.nih...

10

Harnessing radiotherapy-induced NK-cell activity by combini..:

Patin, Emmanuel C ; Dillon, Magnus T ; Nenclares, Pablo...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938703/. , 2022

Link: http://www.ncbi.nlm.nih...

11

Predicting progression-free survival after systemic therapy..:

Barber, Paul R ; Mustapha, Rami ; Flores-Borja, Fabian...
https://discovery.ucl.ac.uk/id/eprint/10162955/1/elife-73288-v2.pdf. , 2022

Link: https://discovery.ucl.ac..

12

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection i..:

McLaughlin, Martin ; Pedersen, Malin ; Roulstone, Victoria...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047134/. , 2020

Link: http://www.ncbi.nlm.nih...

13

Patritumab or placebo, with cetuximab plus platinum therapy..:

Forster, Martin D ; Dillon, Magnus T ; Kocsis, Judit...
European Journal Of Cancer. -123 (2019), p. 36-47. -Eur. J. Cancer. - 0959-8049. , 2019

Link: http://hdl.handle.net/24..

14

An orally bioavailable Chk1 inhibitor, CCT244747, sensitize..:

Patel, Radhika ; Barker, Holly E ; Kyula, Joan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155495/. , 2017

Link: http://www.ncbi.nlm.nih...

15

Predicting progression-free survival after systemic therapy..:

Paul R Barber ; Rami Mustapha ; Fabian Flores-Borja...
https://elifesciences.org/articles/73288. , 2022

Link: https://doi.org/10.7554/..